top of page

Medical Marijuana Research Act of 2019

  • Jason
  • Jul 29, 2019
  • 2 min read

It is interesting that everyone, no matter their stance on the issue of legalization, is in favor of research into medical marijuana. Parties from all sides are co-sponsoring a cannabis bill. Many agree that the government should not interfere with legitimate, scientific, medical research of cannabis. Pro-legalization advocates, law enforcement, medical and scientific communities as well as policy lawmakers all agree that there are foundational barriers within the current regulatory program. These barriers make it difficult to conduct research and access objective evidence as to the medicinal properties of cannabis.


Back in 2016, when the Medical Marijuana Research Act was introduced, there were 25 medical states, with 4 of those 25 also being recreational. After the election, 4 more states joined the medical side and the number of recreational went to 8. Then in 2018 recreational use came to Michigan while medical arrived in Missouri and Utah. Today, 33 states have medical programs and 11 states have now gone recreational. While there is disagreement on the medicinal value of cannabis, everyone agrees that the barriers to cannabis research have blocked the ability to evaluate the risks and benefits associated with cannabis use and to make a responsible policy governing the use. Additionally, there is the burden of the registration process, redundant protocol reviews, absence of proper research material, and needlessly onerous security requirements.


In 2017, the National Academies of Sciences, Engineering, and Medicine, reported “The research on the health effects of cannabis and cannabinoids has been limited in the US leaving patients, healthcare professionals, and policy lawmakers without the evidence they need to make sound decisions regarding the use of cannabis and cannabinoids. This lack of evidence-based information on the health effects of cannabis and cannabinoids poses a public health risk.” The Medical Marijuana Research Act of 2019 would ensure that legitimate research can be conducted on cannabis. The bill would streamline the troubling process and often duplicative licensure process for researchers looking to conduct cannabis research, while maintaining all needed safeguards against misuse and abuse. The bill also addresses the woefully inadequate, dually in quality & quantity, supply of medical grade cannabis available for use in such research. Lastly, it requires that within 5 years (at most) after enactment a report by the secretary of the US Dept of Health & Human services on the status and results of the currently available body of research on cannabis be provided. It is an irrefutable fact that marijuana legalization is rising across America.


 
 
 

Comments


Food and Drug Administration (FDA) Disclosure

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the agronomed.com website. Links to any informational websites are provided solely as a service to our users.

The link provides additional information that may be useful or interesting and has no affiliation to the promotion, sale and distribution of Agronomed products. The link does not constitute an endorsement of these organizations by Agronomed and none should be inferred. Please view our full Terms of Use Agreement for more information and the terms and conditions governing your use of this site.

Cannabidiol (CBD) is a naturally occurring constituent of the industrial hemp plant.

Agronomed does not sell or distribute any products that are in violation of the United States Controlled Substance Act (US.CSA). The company does grow, sell and distribute hemp based products.

© 2018 Copyright Agronomed Pharmaceuticals LLC. All rights reserved. 

bottom of page